Customer story
ASCERTAIN for affordability and sustainability of innovative health tech
"As we had another funding application process going on for us, the support from Spinverse was indispensable during the application process and the Grant Agreement Preparation phase. An external consultant like Spinverse was able to provide us with essential expertise on such a complex process and complemented our somewhat scarce resources, whilst helping us reach the successful outcome."
Carin Uyl-de Groot, Professor, Erasmus School of Health Policy & Management.
Customer story in numbers
5
MILLION € (total budget)
4
YEARS
9
PARTNERS
Funding instrument
Horizon Europe
Together with nine partners, Erasmus School of Health Policy & Management, has now launched the ASCERTAIN project (Affordability and Sustainability improvements through new pricing, Cost-Effectiveness and Reimbursement models to Appraise iNnovative health technologies) aiming to improve the affordability and sustainability of innovative health technologies.
Key challenges
Started in December 2022, the four-year project ASCERTAIN addresses the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe.
How we reached the goals
Spinverse funding experts supported the consortium in its successful funding proposal process. Spinverse also contributed to the process in mapping the stakeholders in value chain, and contacted and motivated them to join the consortium.
Key takeaways
The project aims to improve the quality of care for cancer patients especially in Eastern Europe. If certain parts of process in the process can be accelerated, the project outcomes can make a life-changing difference to cancer patients. For instance, the consortium will develop some open-access tools for decision makers in European countries to be applied on pricing and reimbursement.
Impact of the project
The project outcomes will help e.g., cancer patients to get a better access to newest pharmaceuticals and innovative technologies throughout Europe and beyond.